Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
March 05, 2025 12:15 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology expands Clinical and Scientific Advisory Board with key industry leaders
The Wistar Institute Discovers a Promising Target in Brain Cancer
February 28, 2025 10:26 ET
|
The Wistar Institute
PHILADELPHIA, PA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram...
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024 16:01 ET
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer
December 03, 2024 13:45 ET
|
The Wistar Institute
PHILADELPHIA, PA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA — (December 3, 2024) — The Wistar Institute’s David B. Weiner, Ph.D. — Executive Vice President, director of the Vaccine &...
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
November 18, 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
August 23, 2024 16:30 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC...
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
July 16, 2024 09:00 ET
|
Flag Therapeutics, Inc.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)